Anais Brasileiros de Dermatologia, Journal Year: 2023, Volume and Issue: 98(3), P. 355 - 372
Published: March 1, 2023
Cutaneous lupus erythematosus is an autoimmune disease of varied clinical expression, which may present as exclusively cutaneous or be one the multiple manifestations systemic erythematosus. Its classification includes acute, subacute, intermittent, chronic and bullous subtypes, are usually identified based on features histopathological laboratory findings. Other non-specific associated with related to activity. Environmental, genetic immunological factors play a role in pathogenesis skin lesions Recently, considerable progress has been made elucidating mechanisms involved their development, allows for foreseeing future targets more effective treatments. This review proposes discuss main etiopathogenic, clinical, diagnostic therapeutic aspects erythematosus, aiming update internists specialists from different areas.
Language: Английский
Citations
32
Frontiers in Allergy, Journal Year: 2022, Volume and Issue: 3
Published: June 20, 2022
Drug-induced photosensitivity (DIP) is a common cutaneous adverse drug reaction, resulting from the interaction of ultraviolet radiations, mostly A, with drugs. DIP includes phototoxicity and photoallergy. A phototoxic reaction obtained when topical systemic drugs or their metabolites absorb light inducing direct cellular damage, while photoallergic takes place between radiations causes an immune response. Clinically, immediate appears as exaggerated sunburn, whereas photoallergy delayed eczematous reaction. may show several clinical subtypes. In this mini-review we report pathogenetic mechanisms causative DIP. We offer detailed description features in its classical unusual subtypes, such hyperpigmentation/dyschromia, pseudoporphyria, photo-onycolysis, eruptive teleangiectasia, pellagra-like lichenoid photodistributed erythema multiforme subacute/chronic lupus erythematosus. described how physicians early recognize manage DIP, including diagnostic tests to rule out similar conditions. made suggestions on improve sun exposure behaviors patients at risk by means aware use sunscreens, protective clothing recent technologic tools. highlighted lack safety programs addressed who need formal education about condition.
Language: Английский
Citations
24
Frontiers in Medicine, Journal Year: 2024, Volume and Issue: 11
Published: Feb. 1, 2024
Immune checkpoint inhibitor (ICI) use has been associated with numerous autoimmune side effects, known as immune related adverse events (irAEs). Cutaneous irAEs are common and affect up to 50% of patients treated ICIs. There have an increasing number cases reported in the literature regarding ICI-induced subacute cutaneous lupus erythematosus (SCLE). SCLE is important recognize it can result a delayed and/or prolonged skin reaction despite treatment discontinuation. We describe patient gastro-esophageal adenocarcinoma who developed following one cycle nivolumab treatment. A 75-year-old man presented our clinic new photo-distributed rash composed oval scaly pink papules plaques involving his chest arms. Despite topical corticosteroids, he emergency department 1 week later worsening rash. Skin biopsy showed vacuolar interface pattern, along superficial perivascular lymphocytic infiltrate, consistent drug eruption. The clinicopathological presentation was SCLE. Nivolumab discontinued due severity remitted systemic high potency steroids, hydroxychloroquine. Unfortunately, intraperitoneal metastatic disease, enrolled hospice care. In this paper, we highlight importance early identification irAE. review literature, including discussion on management also provided.
Language: Английский
Citations
4
Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16
Published: March 28, 2025
The use of immune checkpoint inhibitors (ICI) can lead to immune-related adverse events (irAE), which skin irAE is common, affecting up 50% ICI-treated patients. Although only a few cases subacute cutaneous lupus erythematosus (SCLE) have been reported in patients receiving anti-programmed death-1(anti-PD-1) immunotherapy, it important identify ICI-induced SCLE because may cause delayed and/or prolonged reactions even after treatment discontinuation. To date, no associated with Camrelizumab reported. We report case patient advanced non-small cell lung cancer (NSCLC) who gradually developed erythematous rashes on sun-exposed pruritus one course anti-PD-1 antibody combined chemotherapy. were initially considered as eczema, but did not improve symptomatic treatment. continued worsen the third treatment, and was unbearable. After testing, found positive anti-SS-A/Ro antibody, histological changes consistent erythematosus. controlled local systemic glucocorticoids, hydroxychloroquine, discontinuation therapy. be appearance regions, rapidly relieved by glucocorticoids hydroxychloroquine. It recommended perform early testing biopsy for diagnosis Unlike classic drug-related SCLE, develop multiple autoimmune diseases, caution should taken when using subsequent
Language: Английский
Citations
0
Frontiers in Medicine, Journal Year: 2023, Volume and Issue: 9
Published: Jan. 9, 2023
Lupus erythematosus (LE) is an autoimmune inflammatory disease with a wide clinical spectrum from life-threatening multi-organ inflammation in systemic lupus (SLE) to limited skin cutaneous LE (CLE). The etiology of CLE still not fully understood but multifactorial genesis genetic predisposition and certain environmental factors as triggers for the development are generally accepted features. Lesions can be induced aggravated by UV-irradiation smoking linked more severe forms co-morbidity. Drugs, including many common medicines like antihypertensives, known induce subacute (SCLE). mechanisms involved have recently been shown part IFN-I pathway new, specific treatments currently trials. classified subtypes based on presentation duration into acute (ACLE), SCLE, chronic (CCLE). Distinct seen individual patients or coexist within same patient. Because confluent overlapping picture between these subsets, serology, histopathology constitute important role guiding towards correct diagnose there ongoing work update classification. Cutaneous Area Severity Index (CLASI) validated tool measure activity damage both trials also clinician evaluate treatment follow course among patients. substantial impact life those affected. Several tools proposed QoL patients, Skindex-29 probably most used. Patient education prevention flares, UV-protection cessation. First-line includes topical corticosteroids well calcineurin inhibitors addition antimalarials therapy resistant cases. Treatment specifically targeting has lacking, however novel potential therapies later phase In this review we aim describe different subsets form focus aspects.
Language: Английский
Citations
10
JDDG Journal der Deutschen Dermatologischen Gesellschaft, Journal Year: 2025, Volume and Issue: unknown
Published: May 8, 2025
Language: Английский
Citations
0
Immunology and Allergy Clinics of North America, Journal Year: 2022, Volume and Issue: 42(2), P. 219 - 238
Published: March 31, 2022
Language: Английский
Citations
14
Cell Proliferation, Journal Year: 2022, Volume and Issue: 56(7)
Published: Aug. 12, 2022
Abstract Objectives Glioma is one of the most aggressive brain tumours with poor overall survival despite advanced technology in surgical resection, chemotherapy and radiation. Progression recurrence are hinge causes low survival. Our aim to explain concrete mechanism proliferation progression based on tumour microenvironment (TME). The main purpose illustrate proton pump inhibitors (PPIs) affecting acidity, hypoxia, oxidative stress, inflammatory response autophagy TME induce apoptosis enhance sensitivity chemoradiotherapy. Findings medium for growth progression. Acidity, response, autophagy, angiogenesis so progress. PPIs, as a common clinical drug inhibit gastric acid secretion, have advantages fast onset, long action time small adverse reactions. Nowadays, several kinds literature highlight potential PPIs inhibiting However, long‐term use alone also has obvious side effects. Therefore, till now, how apply promote effect radio‐chemotherapy find dose concentration combined novel challenges. Conclusions display enhancing chemoradiotherapy defend against glioma TME. In clinic, it necessary explore specific concentrations dosages synthetic applications.
Language: Английский
Citations
12
La Revue de Médecine Interne, Journal Year: 2024, Volume and Issue: 45(9), P. 559 - 599
Published: Aug. 27, 2024
Because Systemic Lupus Erythematosus (SLE) is a rare disease, and due to the significant prognostic impact of early management, diagnosis confirmed by physician with experience in SLE recommended, for example from an expert center. Once confirmed, existing manifestations should be identified particular, renal involvement assessment proteinuria, disease activity severity determined, potential complications anticipated, associated diseases searched for, patient's socioprofessional family context noted. Therapeutic management includes patient education on recognizing symptoms, understanding progression as well when they seek medical advice. Patients are informed about routine checkups, treatment side effects, need regular vaccinations, especially if receiving immunosuppressive treatment. They also advised lifestyle factors such risks smoking, sun exposure, dietary adjustments, corticosteroids. The importance contraception, particularly teratogenic medications being used, cancer screening emphasized. Support networks can help relieve isolation. first-line hydroxychloroquine (HCQ), possibly combined immunosuppressant and/or low-dose corticosteroid therapy. flares depends their severity, typically involves HCQ NSAIDs, but may escalated therapy immunosuppressants or biologic therapies moderate severe cases. there no curative treatment, goals comfort, preventing flares, preserving overall long-term health fertility. frequency follow-up visits any new symptoms. Regular specialized assessments necessary, changes, every 3 6 months recommended during periods remission monthly active children. These include both clinical laboratory tests monitor activity, specific attention proteinuria.
Language: Английский
Citations
2
Therapies, Journal Year: 2023, Volume and Issue: 79(2), P. 239 - 270
Published: Oct. 31, 2023
Language: Английский
Citations
6